The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers.
Gamma-vinyl-gamma-aminobutyric acid (GVG) elevates central nervous system gamma-aminobutyric acid (GABA) levels by irreversibly inhibiting GABA transaminase. An open-label clinical trial in humans suggested that GVG may reduce cocaine and methamphetamine use. To test safety and to obtain preliminary data on efficacy of GVG for treating methamphetamine dependence, we conducted a double-blind, placebo-controlled, parallel group study of GVG interaction with the cardiovascular and subjective effects produced by methamphetamine. Non-treatment seeking methamphetamine-dependent volunteers received either GVG (N=8) or placebo (N=9) by random assignment. GVG treatment was initiated at 1 g/day and increased to 5 g/day. After reaching the target dose of 5 g/day, participants received methamphetamine (15+30 mg, IV), and cardiovascular and subjective effects were assessed. No serious adverse events were noted, and the total number of adverse events was similar between the treatment groups. Considering the full time course and peak effects independently, no significant differences were detected between the groups for systolic or diastolic blood pressures, or heart rate, following methamphetamine exposure. Some methamphetamine-induced cardiovascular changes approached significance (p<0.10) and may warrant attention in future trials. Methamphetamine-induced subjective effects ("any drug effect", "high", "crave methamphetamine") were statistically similar between GVG and placebo treatment groups. Pharmacokinetic data indicate that GVG treatment did not alter methamphetamine or amphetamine plasma levels, and there was no association between methamphetamine or amphetamine plasma levels and peak cardiovascular effects. Taken together, the data indicate that GVG treatment is generally well tolerated but not efficacious in attenuating the positive subjective effects of methamphetamine in the laboratory.
De La Garza
Richard
R
Baylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, USA. richard.delagarza@bcm.edu
Zorick
Todd
T
Heinzerling
Keith G
KG
Nusinowitz
Steve
S
London
Edythe D
ED
Shoptaw
Steven
S
Moody
David E
DE
Newton
Thomas F
TF
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors*; D000328:Adult; D019969:Amphetamine-Related Disorders / Q000150:complications / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003863:Depression / Q000150:complications; D004311:Double-Blind Method; D005260:Female; D018682:GABA Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008694:Methamphetamine / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D008875:Middle Aged; D012054:Reinforcement, Psychology; D020888:Vigabatrin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014794:Visual Fields / Q000187:drug effects
D000697:Central Nervous System Stimulants; D018682:GABA Agents; D008694:Methamphetamine; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin
J Clin Psychiatry. 2003 Dec;64(12):1440-8
14728105
Drug Alcohol Depend. 2007 Dec 1;91(2-3):141-8
17629631
Synapse. 1998 Oct;30(2):119-29
9723781
Epilepsia. 1999 Oct;40(10):1433-8
10528940
Drug Alcohol Depend. 2005 Oct 1;80(1):53-61
16157231
Drug Alcohol Depend. 2006 Feb 28;81(3):267-74
16169160
Drug Alcohol Depend. 2007 Feb 23;87(1):1-9
16930857
Addiction. 2005 Mar;100 Suppl 1:68-77
15730351
J Pharmacol Exp Ther. 1999 Aug;290(2):797-802
10411594
Drug Alcohol Depend. 2004 Mar 8;73(3):279-87
15036550
Psychiatry Res. 2007 Aug 30;152(2-3):205-10
17449110
Int J Neuropsychopharmacol. 2008 Sep;11(6):729-41
18248689
Drug Alcohol Depend. 2004 Sep 6;75(3):233-40
15283944
Neuropsychopharmacology. 2006 Jul;31(7):1537-44
16319910
Psychopharmacology (Berl). 2005 Nov;182(4):516-26
16075286
Pharmacol Biochem Behav. 2005 Sep;82(1):90-7
16112720
Drug Alcohol Depend. 2004 Oct 5;76(1):81-91
15380292
Hypertension. 1993 Dec;22(6):819-25
7902334
Arch Ophthalmol. 2006 Sep;124(9):1257-62
16966620
Pharmacol Biochem Behav. 2005 Nov;82(3):569-73
16332385
Int J Neuropsychopharmacol. 2008 Dec;11(8):1037-45
18664303
Neuropsychopharmacology. 2008 Apr;33(5):1162-70
17581531
Int J Neuropsychopharmacol. 2007 Feb;10(1):85-98
16448579
Psychopharmacology (Berl). 2004 Feb;171(4):441-9
14504683
Synapse. 2003 Dec 1;50(3):261-5
14515344
Drug Alcohol Depend. 2006 Dec 1;85(3):177-84
16740370
Life Sci. 1999;65(11):1175-82
10503933
Drug Alcohol Depend. 2008 Aug 1;96(3):222-32
18468815
Synapse. 1999 Oct;34(1):11-9
10459167
Drug Alcohol Depend. 2007 Jan 12;86(2-3):274-7
16879931
Addiction. 2005 Mar;100 Suppl 1:58-67
15730350
Synapse. 2001 Sep 1;41(3):219-20
11391783
Behav Pharmacol. 2007 Feb;18(1):71-5
17218799
Synapse. 2005 Feb;55(2):122-5
15543630
Neuropharmacology. 1993 Jun;32(6):575-9
8336820
Neuropsychopharmacology. 2006 Aug;31(8):1814-21
16407903
Drug Alcohol Depend. 2005 Dec 12;80(3):369-76
16005580